α-2b干扰素治疗HBeAg阳性慢性乙型肝炎临床分析

目的 观察普通α-2b干扰素（IFN）和聚乙二醇干扰素（PEG IFN）α-2b治疗HBeAg阳性慢性乙型肝炎抗病毒的临床疗效.方法 HBeAg阳性慢性乙型肝炎患者64例,36例给予普通α-2b干扰素抗病毒治疗,每次500万U,皮下注射,每周3次; 28例给予聚乙二醇干扰素α-2b 1.0 μg/kg皮下注射,每周1次.疗程均为52周.结果 治疗结束时,普通干扰素组与PEG IFN组的完全应答率分别为52.8%、60.7%;部分应答率分别为27.8%、21.4%;无应答率分别为19.4%、17.9%,两组比较差异无统计学意义（P〉0.05）.治疗结束时普通干扰素α-2b组,PEG-IFN α-2b组丙氨酸氨基转移酶（ALT）复常率分别是81.7%、85.9%,二者比较差异无统计学意义（P〉0.05）.普通干扰素α-2b组与PEG-IFN α-2b组在52周治疗结束时HBV DNA阴转率分别为49.3%、57.6%,二者比较差异无统计学意义（P〉0.05）.结论 两种不同剂型的α-2b干扰素治疗HBeAg阳性慢性乙型肝炎的应答率相似,普通干扰素具有更好的成本效益.

Clinical analysis of interferon alpha 2b antiviral therapy for HBeAg positive chronic hepatitis B patients

Objective To observe the clinical efficacy of interferon alphct-2b（IFN ct-2b） and Pegylated interferon alphc-2b （PEG-IFN a-2b） on HBeAg positive chronic hepatitis B. Methods Sixty-four patients with HBeAg positive chronic hepatitis B were enrolled into this study. Thirty-six patients received IFN ct-2b（ group IFN c-2b） , 5MU SC, three times a week; and 28 pa- tients were treated with PEG-IFN c-2b （ group PEG-IFN c-2b ）, 1.0 p,g/kg body weight, SC, once a week for 52 weeks. Results The complete response rate was 52. 8% in group IFN c-2b and 60. 7% in group PEG-IFN c-2b. The partial response rate was 27. 8% in group IFN ct-2b, and 21.4% in Peg IFN c-2b. The no response rate was 19. 4% in group IFN ct-2b and 17.9% in group Peg IFN ct-2b. There was no significant difference in the response rates at the end of treatment between group IFN a-2b and group PEG-IFN c-2b. The ALT normalization rate was 81.7% in IFN c-2b group and 85.9% in group PEG-IFN c-2b, ALT normalization rate had no statistical difference at the end of treatment between the two groups. The rates of HBV DNA negative were 49.3% and 57.6%, respectively, there was no significant difference after 52 weeks treatment. Conclusion The efficacy of seems to be similar that the two different formulations of interferon c-2b treatment for HBeAg positive chronic hepatitis B, but regular IFN a-2b has better cost-benefit.